- Stocks
- Pharma & Healthcare
- Laurus Labs
Laurus Labs share price
NSE: LAURUSLABSPharma & HealthcareDrug Manufacturers - Specialty & Generic
Laurus Labs at a glance
Laurus Labs (NSE: LAURUSLABS) closed at ₹2,061.90 on 19 Oct 2026, up 0.17% on the day. With a market capitalisation of ₹1,11,394 Cr, it ranks 89th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 124.8× trailing earnings, against a return on equity of 8.0% in FY25. Over the past year the share price has risen 135.1%. Its 52-week range is ₹901.40 (20 Oct 2025) to ₹2,089.00 (19 Oct 2026); the last close is 1.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,026 Cr (+29.1% year on year) and net profit ₹362 Cr (+124.7%), on a consolidated basis. Promoters held 27.47% of the company as of 30 Jun 2026; 2.69% of promoter shares were pledged.
Key numbers
- Market cap
- ₹1,11,394 CrRank 89 on NSE
- P/E (trailing)
- 124.8×
- Price to book
- 7.4×FY25
- EPS (TTM)
- ₹20.26to Q1 FY27
- ROE
- 8.0%FY25
- ROCE
- 11.8%FY25
- Debt to equity
- 0.6FY25
- Net profit margin
- 6.4%FY25
- Book value / share
- ₹82.99FY25
- Dividend payout
- 12.0%FY25
- 52-week high
- ₹2,089.0019 Oct 2026
- 52-week low
- ₹901.4020 Oct 2025
- 1-year return
- +135.1%
- RSI (14-day)
- 61.3
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.17% | +1.0% | +5.3% | +32.2% | +135.1% |
Laurus Labs quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,224 Cr | ₹1,415 Cr | ₹1,720 Cr | ₹1,570 Cr | ₹1,653 Cr | ₹1,778 Cr | ₹1,812 Cr | ₹2,026 Cr |
| Revenue YoY | −0.1% | +18.4% | +19.5% | +31.4% | +35.1% | +25.7% | +5.3% | +29.1% |
| Net profit | ₹18 Cr | ₹91 Cr | ₹234 Cr | ₹161 Cr | ₹194 Cr | ₹253 Cr | ₹282 Cr | ₹362 Cr |
| Net profit YoY | −54.9% | +260.0% | +210.5% | +1,219.2% | +993.4% | +179.3% | +20.5% | +124.7% |
| Net margin | 1.4% | 6.4% | 13.6% | 10.3% | 11.7% | 14.2% | 15.6% | 17.9% |
| EPS | ₹0.37 | ₹1.71 | ₹4.34 | ₹3.02 | ₹3.61 | ₹4.67 | ₹5.17 | ₹6.81 |
Laurus Labs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹2,832 Cr | ₹4,814 Cr | ₹4,936 Cr | ₹6,041 Cr | ₹5,041 Cr | ₹5,554 Cr |
| Operating profit | ₹294 Cr | ₹1,301 Cr | ₹1,084 Cr | ₹1,109 Cr | ₹236 Cr | ₹484 Cr |
| Net profit | ₹255 Cr | ₹984 Cr | ₹832 Cr | ₹797 Cr | ₹168 Cr | ₹354 Cr |
| EPS (₹) | ₹24.00 | ₹18.00 | ₹15.00 | ₹15.00 | ₹3.00 | ₹7.00 |
| Cash from operations | ₹347 Cr | ₹733 Cr | ₹911 Cr | ₹994 Cr | ₹666 Cr | ₹602 Cr |
| Total debt | ₹165 Cr | ₹429 Cr | ₹596 Cr | ₹761 Cr | ₹798 Cr | ₹646 Cr |
| Shareholders' equity | ₹1,770 Cr | ₹2,598 Cr | ₹3,351 Cr | ₹4,038 Cr | ₹4,111 Cr | ₹4,473 Cr |
Laurus Labs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 27.62% | 27.59% | 27.59% | 27.49% | 27.49% | 27.47% |
| Foreign institutions | 25.52% | 25.70% | 26.16% | 26.52% | 25.82% | 28.00% |
| Domestic institutions | 11.77% | 11.94% | 11.73% | 12.43% | 13.97% | 13.74% |
| Non-institutions | 35.09% | 34.77% | 34.51% | 33.56% | 32.71% | 30.78% |
| Promoter shares pledged | 2.69% | 2.69% | 2.69% | 2.69% | 2.69% | 2.69% |
Laurus Labs vs peers
The listed Pharma & Healthcare companies nearest to Laurus Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| LAURUSLABSLaurus Labs | ₹2,061.90 | +0.17% | +135.1% | ₹1,11,394 Cr | 124.8 | — |
| ZYDUSLIFEZydus Lifesciences | ₹1,111.50 | −1.23% | +11.9% | ₹1,10,873 Cr | 22.2 | — |
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,695.00 | −1.75% | +0.1% | ₹1,10,642 Cr | 57 | — |
| CIPLACipla | ₹1,324.00 | −0.12% | −15.6% | ₹1,06,959 Cr | 27.5 | — |
| DRREDDYDr. Reddy's Laboratories | ₹1,241.20 | +0.89% | −1.8% | ₹1,03,600 Cr | — | — |
| AUROPHARMAAurobindo Pharma | ₹1,617.00 | −2.54% | +43.1% | ₹93,039 Cr | 26.8 | — |
| MANKINDMankind Pharma | ₹2,251.00 | −1.11% | −8.5% | ₹92,965 Cr | 48.7 | — |
Ask anything about Laurus Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against LAURUSLABS's own history. Try: “Why has LAURUSLABS moved over the last three months?” · “Backtest a 50-day moving-average crossover on LAURUSLABS over five years” · “Compare LAURUSLABS with ZYDUSLIFE on margins and valuation”
Frequently asked questions about Laurus Labs
What is the share price of Laurus Labs today?
Laurus Labs (NSE: LAURUSLABS) last closed at ₹2,061.90 on 19 Oct 2026. Its 52-week high is ₹2,089.00 and its 52-week low is ₹901.40.
What is the market cap of Laurus Labs?
Laurus Labs' market capitalisation is ₹1,11,394 Cr (₹1.11 lakh Cr) at the 19 Oct 2026 close, ranking 89th among the NSE companies Pivot tracks.
What is the P/E ratio of Laurus Labs?
Laurus Labs trades at a trailing P/E of 124.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 27.5.
What is the ROE and ROCE of Laurus Labs?
Return on equity was 8.0% in FY25 and return on capital employed was 11.8% in FY25 (consolidated figures).
Is Laurus Labs a debt-free company?
No. Laurus Labs' debt-to-equity ratio was 0.6 in FY25, with total debt of ₹646 Cr.
What were Laurus Labs' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Laurus Labs reported revenue of ₹2,026 Cr, +29.1% year on year, and net profit of ₹362 Cr, +124.7% year on year.
How has Laurus Labs stock performed over the last year?
Laurus Labs' share price has risen 135.1% over the past year, +32.2% over three months and +5.3% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Laurus Labs?
As of 30 Jun 2026: promoters 27.47%, foreign institutions 28.00%, domestic institutions 13.74%, non-institutions 30.78%. 2.69% of promoter shares were pledged.
Who are Laurus Labs' competitors?
The listed Pharma & Healthcare companies closest to Laurus Labs by market cap are Zydus Lifesciences, Apollo Hospitals Enterprise, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma and Mankind Pharma.
Is Laurus Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Laurus Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LAURUSLABS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with L · all NSE stocks · this page as text